Major Market Shift in Gestational Diabetes Industry: Impact Of Rising Obesity Rates On Healthcare Demand

What Is the Forecasted Market Size and Growth Rate for the Gestational Diabetes Market?
The market size for gestational diabetes has shown robust growth in recent times. The market is projected to expand from $8.37 billion in 2024 to $9.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.3%. Factors that contributed to the remarkable growth during the historical period include a rise in diabetes risk, improved accuracy in blood glucose level measurement, escalation in the number of insurance providers, an increase in the diabetic patient population, and overall growth in the diabetes community.

The market size for gestational diabetes is projected to witness considerable expansion in the forthcoming years. The market is anticipated to reach a valuation of $12.90 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.0%. Factors contributing to the growth during the forecast period include a surge in obesity figures, wider acceptance of cloud-based project systems, and increased use of associated devices and applications. Additionally, the augmented prevalence of diabetes owing to unhealthy lifestyle habits among individuals, enhanced public health awareness, escalating diabetes prevalence rates are also playing a role. Noteworthy trends during the forecast period comprise digital diabetes management apps, sealed control systems, diabetes management technology, enzymatic technology, and inventive medical technologies.

What Factors Are Propelling the Expansion of the Gestational Diabetes Market?
The expansion of the gestational diabetes market is anticipated to be propelled by the growing number of obese individuals. Obese individuals are those with a body mass index (BMI) of 30 or above, suggesting excessive body fat that could lead to considerable health hazards. The rise in obesity is a result of inactive lifestyles, higher intake of high-calorie, processed foods, genetic predispositions, and restricted availability of healthy food and exercise facilities. It's imperative to treat gestational diabetes in obese individuals due to their increased susceptibility to insulin resistance and abnormal weight gain during pregnancy, which if left untreated, can result in complications for both the mother and the child. For example, in March 2024, the World Health Organization, a Switzerland-based international organization, reported that about 1 in 8 people worldwide were obese in 2022, which includes 2.5 billion adults aged 18 and above being classified as overweight. This group included 890 million individuals suffering from obesity. Of the adult population, 43% were overweight, and 16% were obese. Furthermore, 37 million children below the age of 5 were overweight, with over 390 million children and adolescents aged between 5 to 19 years being overweight or obese, which included 160 million obese individuals. Consequently, the rise in obesity is fueling the growth of the gestational diabetes market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

Which Businesses Are at the Forefront of Gestational Diabetes Market Development?
Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc

What Are the Major Trends Shaping the Gestational Diabetes Market?
Major firms in the gestational diabetes marketplace are prioritising the creation of high-tech products, such as diagnostic kits for gestational diabetes. These kits aim to provide speedy, precise, and user-friendly facilities for rapid detection. These medical devices are used to determine blood sugar levels and detect unusual glucose tolerance in pregnant women, thereby enabling early identification and management of the condition. As an illustration, in August 2024, an Austriabased biotech enterprise, DirectSens GmbH, introduced the XpressGT RUO kit. This diagnostic kit is designed to diagnose gestational diabetes, endometriosis, insulin resistance, and liver illness by accurately measuring the level of 2-hydroxybutyrate (2-HB) found in venous blood, a compound naturally produced by the liver during standard functioning. A rise in 2-HB levels corresponds to increased reductive stress, which is related to several endocrine and obesity-related conditions, including insulin resistance. The kit is compatible with all currently available clinical analysers and produces results in a mere 8 minutes, making it a speedy and effective diagnostic option.

How Is the Gestational Diabetes Market Segmented?
The gestational diabetes market covered in this report is segmented -

1) By Types: Type A1, Type A2, Other Types
2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological treatment
3) By Administration: Oral, Intravenous, Other Administrations
4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

Subsegments:
1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes
2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes
3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

Where Is the Gestational Diabetes Market Growth Most Prominent?
North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Gestational Diabetes Global Market Report?

- Market Size Analysis: Analyze the gestational diabetes Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the gestational diabetes Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall gestational diabetes market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the gestational diabetes market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20818

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.